C Weyer

Summary

Affiliation: Amylin Pharmaceuticals
Country: USA

Publications

  1. ncbi Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study
    Christian Weyer
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Diabetes Care 26:3074-9. 2003
  2. ncbi Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians
    Christian Weyer
    Clinical Diabetes and Nutrition Section, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 4212 N 16th Street Rm 5 41, Phoenix, AZ 85016, USA
    Atherosclerosis 161:233-42. 2002
  3. ncbi Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control
    C Weyer
    Amylin Pharmaceuticals Inc, 9373 Towne Centre Drive, San Diego, CA 92121, USA
    Curr Pharm Des 7:1353-73. 2001
  4. ncbi Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Diabetes 48:2197-203. 1999
  5. ncbi Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Diabetes 47:1555-61. 1998
  6. ncbi Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion
    B Vozarova
    Clinical Diabetes and Nutrition Section, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Obes Res 9:414-7. 2001
  7. ncbi Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Diabetes Care 24:89-94. 2001
  8. ncbi Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Diabetes Care 23:779-85. 2000
  9. ncbi Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA
    Hypertension 36:531-7. 2000
  10. ncbi Determinants of energy expenditure and fuel utilization in man: effects of body composition, age, sex, ethnicity and glucose tolerance in 916 subjects
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ 85016, USA
    Int J Obes Relat Metab Disord 23:715-22. 1999

Detail Information

Publications64

  1. ncbi Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study
    Christian Weyer
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Diabetes Care 26:3074-9. 2003
    ....
  2. ncbi Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians
    Christian Weyer
    Clinical Diabetes and Nutrition Section, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 4212 N 16th Street Rm 5 41, Phoenix, AZ 85016, USA
    Atherosclerosis 161:233-42. 2002
    ..Thus, obesity and insulin resistance appear to be associated with low-grade inflammation and endothelial dysfunction, respectively, even in an obesity- and diabetes-prone population with relatively low propensity for atherosclerosis...
  3. ncbi Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control
    C Weyer
    Amylin Pharmaceuticals Inc, 9373 Towne Centre Drive, San Diego, CA 92121, USA
    Curr Pharm Des 7:1353-73. 2001
    ..Amylin replacement with pramlintide as an adjunct to insulin therapy is a novel physiological approach toward improved long-term glycemic and weight control in patients with type 1 and type 2 diabetes...
  4. ncbi Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Diabetes 48:2197-203. 1999
    ..More severe metabolic abnormalities are present in Pima Indians with combined IFG and IGT...
  5. ncbi Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Diabetes 47:1555-61. 1998
    ..This is the first study to demonstrate unequivocal metabolic effects of a highly selective beta3-adrenoceptor agonist in humans...
  6. ncbi Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion
    B Vozarova
    Clinical Diabetes and Nutrition Section, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Obes Res 9:414-7. 2001
    ....
  7. ncbi Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Diabetes Care 24:89-94. 2001
    ..We therefore assessed the predictive effect of insulin resistance and insulin secretory dysfunction separately for the progression from normal glucose tolerance (NGT) to impaired glucose tolerance (IGT) and from IGT to diabetes...
  8. ncbi Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Diabetes Care 23:779-85. 2000
    ..We hypothesized that an elevated C3 concentration might be linked to insulin resistance and/or hyperinsulinemia, abnormalities commonly observed in association with the above conditions...
  9. ncbi Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA
    Hypertension 36:531-7. 2000
    ..The lack of an increase in SNS activity with increasing adiposity and insulinemia in Pima Indians may contribute to the low prevalence of hypertension in this population...
  10. ncbi Determinants of energy expenditure and fuel utilization in man: effects of body composition, age, sex, ethnicity and glucose tolerance in 916 subjects
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ 85016, USA
    Int J Obes Relat Metab Disord 23:715-22. 1999
    ..24-h energy expenditure (24-EE) and 24-h respiratory quotient (24-RQ) are important measurements in obesity research, but their accurate assessment is limited to few specialized laboratories...
  11. ncbi Exaggerated pancreatic polypeptide secretion in Pima Indians: can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity, and diabetes in humans?
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ 85016, USA
    Metabolism 50:223-30. 2001
    ....
  12. ncbi Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes
    J F Gautier
    Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA
    Diabetes 50:1828-33. 2001
    ..1,255 [1,045-1,505] pmol/l, P < 0.02). Thus, insulin secretion is lower in normal glucose tolerant offspring of people with early onset type 2 diabetes. This impairment may be worsened by exposure to a diabetic environment in utero...
  13. ncbi Relationship between birth weight and body composition, energy metabolism, and sympathetic nervous system activity later in life
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Obes Res 8:559-65. 2000
    ..Programming of metabolic, endocrine, and/or autonomic pathways during intrauterine development has been proposed to explain this association...
  14. ncbi A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Diabetes 49:2094-101. 2000
    ..Whether amelioration of basal insulin hypersecretion will prevent diabetes remains to be elucidated...
  15. ncbi The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus
    M Fineman
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Horm Metab Res 34:504-8. 2002
    ..The aim of this study was to examine whether pramlintide reduces the postprandial hyperglucagonemia that is often seen in this patient population...
  16. ncbi Energy expenditure, fat oxidation, and body weight regulation: a study of metabolic adaptation to long-term weight change
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    J Clin Endocrinol Metab 85:1087-94. 2000
    ..The metabolic responses to weight changes are highly variable among individuals, however...
  17. ncbi Energy metabolism in African Americans: potential risk factors for obesity
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ 85016, USA
    Am J Clin Nutr 70:13-20. 1999
    ..Recent reports have identified a lower resting metabolic rate in African Americans than in whites, but most studies included only females and used short-term measurements with ventilated-hood systems...
  18. ncbi Metabolic factors contributing to increased resting metabolic rate and decreased insulin-induced thermogenesis during the development of type 2 diabetes
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Diabetes 48:1607-14. 1999
    ....
  19. ncbi The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    J Clin Invest 104:787-94. 1999
    ..Thus, defects in insulin secretion and insulin action occur early in the pathogenesis of diabetes. Intervention to prevent diabetes should target both abnormalities...
  20. ncbi Changes in energy metabolism in response to 48 h of overfeeding and fasting in Caucasians and Pima Indians
    C Weyer
    Clinical Diabetes and Nutrition Section, NIDDK, National Institutes of Health, Phoenix, Arizona 85016, USA
    Int J Obes Relat Metab Disord 25:593-600. 2001
    ..To further examine this hypothesis, we assessed the changes in 24 h energy metabolism in response to short-term overfeeding and fasting in Caucasians (C) and Pima Indians (I), a population with a very high propensity for obesity...
  21. ncbi Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ 85016, USA
    Obes Res 7:444-52. 1999
    ..We tested whether fasting and post-prandial plasma ASP concentrations are increased in Pima Indians, a population with a very high prevalence of obesity, but a remarkably low prevalence of dyslipidemia...
  22. ncbi Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    J Clin Endocrinol Metab 86:1930-5. 2001
    ....
  23. ncbi Exaggerated insulin secretion in Pima Indians and African-Americans but higher insulin resistance in Pima Indians compared to African-Americans and Caucasians
    N Stefan
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ, USA
    Diabet Med 21:1090-5. 2004
    ....
  24. ncbi Energy metabolism after 2 y of energy restriction: the biosphere 2 experiment
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ 85106, USA
    Am J Clin Nutr 72:946-53. 2000
    ..An adaptive decrease in energy expenditure (EE) in response to 6 mo of severely restricted energy intake was shown in a classic semistarvation study-the Minnesota experiment...
  25. ncbi Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis
    D Maggs
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Metabolism 52:1638-42. 2003
    ..Thus, pending further experience, the combined improvement in glycemic and weight control with pramlintide treatment appears to be generalizable to a broad population of mixed ethnicity...
  26. ncbi Differences in oral temperature and body shape in two populations with different propensities for obesity
    B Vozarova
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Ann N Y Acad Sci 967:516-21. 2002
    ..We hypothesized that Pima Indians, a population with a high prevalence of abdominal obesity, may have a lower surface area relative to volume, that is, lower radiating area, and therefore a higher body temperature compared to Caucasians...
  27. ncbi Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone
    Steven V Edelman
    Veterans Affairs Health Care Systems, V111G Endocrinology, University of California San Diego, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    Diabetes Technol Ther 4:175-89. 2002
    ....
  28. ncbi The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes
    M S Fineman
    Clinical Science, Amylin Pharmaceuticals Inc, 9373 Towne Centre Drive, San Diego, CA 92121, USA
    Metabolism 51:636-41. 2002
    ....
  29. ncbi Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update
    C Weyer
    National Institutes of Health, Phoenix, AZ
    Diabetes Metab 25:11-21. 1999
    ....
  30. ncbi The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus
    R E Pratley
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA
    Diabetologia 44:929-45. 2001
    ..Strategies that enhance early insulin secretion improve glucose tolerance and represent a novel and more physiologic approach to improving glycaemic control in patients with Type II diabetes mellitus...
  31. ncbi Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats
    J D Roth
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Int J Obes (Lond) 32:1201-10. 2008
    ..To characterize the interactive effects of amylin with phentermine or sibutramine on food intake, body weight/composition and gene expression in diet-induced obese (DIO) rats...
  32. ncbi Comparison of two software versions for assessment of body-composition analysis by DXA
    B Vozarova
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Obes Res 9:229-32. 2001
    ..To compare two software versions provided by Lunar CO: for assessment of body composition analysis by DXA...
  33. ncbi Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21--q23 and is associated with a common polymorphism in LMNA in Pima Indians
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 4212 N 16th Street, Phoenix, Arizona 85016, USA
    Mol Genet Metab 72:231-8. 2001
    ..c. abd. AS can be attributed to familial factors and that genetic variation in LMNA might not only underlie rare cases of FPLD, but may also contribute to variation in adipocyte size in the general population...
  34. ncbi Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies
    Jonathan D Roth
    Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 105:7257-62. 2008
    ....
  35. ncbi Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects
    Tim Heise
    Profil Institute for Metabolic Research, Neuss, Germany
    Metabolism 53:1227-32. 2004
    ..These results showed that pramlintide did not impair the symptom, catecholamine, and glucagon responses to insulin-induced hypoglycemia in healthy subjects...
  36. ncbi Endogenous glucose production, insulin sensitivity, and insulin secretion in normal glucose-tolerant Pima Indians with low birth weight
    Norbert Stefan
    The Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ, USA
    Metabolism 53:904-11. 2004
    ..We conclude that interaction of multiple defects may contribute to increased susceptibility to type 2 diabetes among individuals with LBW...
  37. ncbi Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients
    Priscilla Hollander
    Baylor College of Medicine, Dallas, Texas, USA
    Obes Res 12:661-8. 2004
    ..001), for placebo-corrected reductions of -3.2 kg and -2.5 kg, respectively. DISCUSSION: These findings support further evaluation of the weight-lowering potential of pramlintide in obese patients with type 2 diabetes...
  38. ncbi Pancreatic polypeptide is involved in the regulation of body weight in pima Indian male subjects
    Juraj Koska
    Clinical Diabetes and Nutrition Section, National Institutes of Digestive and Kidney Diseases, National Institutes of Health, 4212 N 16th St, Rm 5 41, Phoenix, AZ 85016, USA
    Diabetes 53:3091-6. 2004
    ..However this contribution appears to be more complex than anticipated because of the opposite effect of fasting and postprandial PP on the risk of future weight gain...
  39. ncbi Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes
    Antonio Ceriello
    Department of Pathology and Medicine, Experimental and Clinical, University of Udine, Italy
    Diabetes Care 28:632-7. 2005
    ..001 for all correlations). CONCLUSIONS: These findings indicate that the postprandial glucose-lowering effect of pramlintide in type 1 diabetes is associated with a significant reduction in postprandial oxidative stress...
  40. ncbi Properties of pramlintide and insulin upon mixing
    Christian Weyer
    Regulatory and Medical Information, Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA
    Am J Health Syst Pharm 62:816-22. 2005
    ....
  41. ncbi Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects
    Ian Chapman
    Department of Medicine, University of Adelaide, Royal Adelaide Hospital, North Terrace, Adelaide, Australia
    Obesity (Silver Spring) 15:1179-86. 2007
    ..To further characterize the meal-related effects of amylin signaling in humans, we studied a lower pramlintide dose (30 microg) in normal-weight subjects...
  42. ncbi Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study
    Louis Aronne
    Weill Cornell Medical College, New York, NY 10021, USA
    J Clin Endocrinol Metab 92:2977-83. 2007
    ..In previous 1-yr trials, treatment with pramlintide (120 microg), an analog of the beta-cell hormone amylin, induced sustained reductions in A1C and body weight in insulin-using subjects with type 2 diabetes...
  43. ncbi Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study
    Steven R Smith
    Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA
    Am J Physiol Endocrinol Metab 293:E620-7. 2007
    ....
  44. ncbi Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity
    Jonathan D Roth
    Amylin Pharmaceuticals Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Endocrinology 148:6054-61. 2007
    ..Collectively, these observations highlight the importance of studying peptide hormones in combination and suggest that integrated neurohormonal approaches may hold promise as treatments for obesity...
  45. ncbi Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity
    Steve R Smith
    Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA
    Diabetes Care 31:1816-23. 2008
    ..To assess long-term weight loss efficacy and safety of pramlintide used at different dosing regimens and in conjunction with lifestyle intervention (LSI)...
  46. ncbi Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals
    Juraj Koska
    Obesity and Diabetes Clinical Research Section, NIDDK NIH DHHS, Phoenix, AZ 85016, USA
    Am J Clin Nutr 87:295-302. 2008
    ....
  47. ncbi Parasympathetic blockade attenuates augmented pancreatic polypeptide but not insulin secretion in Pima Indians
    Barbora Vozarova de Courten
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA
    Diabetes 53:663-71. 2004
    ..However, the hyperinsulinemia of this population does not appear to be due to increased vagal input to pancreatic beta-cells...
  48. ncbi Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study
    David G Maggs
    Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
    Diabetes Metab Res Rev 20:55-60. 2004
    ..To assess the postprandial glucose-lowering effect of the human amylin analog pramlintide when given with insulin lispro in subjects with type 2 diabetes, with an emphasis on the optimal dose timing relative to meals...
  49. ncbi A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
    Fred Whitehouse
    Henry Ford Hospital, Detroit, Michigan, USA
    Diabetes Care 25:724-30. 2002
    ..CONCLUSIONS: Mealtime pramlintide treatment as an adjunct to insulin improved long-term glycemic control without inducing weight gain or increasing the overall risk of severe hypoglycemia in patients with type 1 diabetes...
  50. ncbi Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes
    Robert E Ratner
    MedStar Research Institute, Washington, DC, USA
    Diabetes Technol Ther 4:51-61. 2002
    ....
  51. ncbi Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans
    Norbert Stefan
    Clinical Diabetes and Nutrition Section, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA
    Diabetes 51:1884-8. 2002
    ..Prospectively, low plasma adiponectin concentration at baseline precedes a decrease in insulin sensitivity. Our data indicate that adiponectin plays an important role in regulation of insulin sensitivity in humans...
  52. ncbi Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity
    Jonathan Q Purnell
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon 97201, USA
    Treat Endocrinol 2:33-47. 2003
    ....
  53. ncbi Assessing risk factors for obesity between childhood and adolescence: II. Energy metabolism and physical activity
    Arline D Salbe
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Pediatrics 110:307-14. 2002
    ....
  54. ncbi Low plasma adiponectin concentrations do not predict weight gain in humans
    Barbora Vozarova
    National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA
    Diabetes 51:2964-7. 2002
    ..Therefore, the predictive effect of low plasma adiponectin concentrations on the development of type 2 diabetes seems to be mediated by factors other than increased adiposity...
  55. ncbi Plasma adiponectin levels are not associated with fat oxidation in humans
    Norbert Stefan
    Clinical Diabetes and Nutrition Section, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Obes Res 10:1016-20. 2002
    ..To test the hypothesis that low adiponectin is associated with low fat oxidation in humans...
  56. ncbi Assessing risk factors for obesity between childhood and adolescence: I. Birth weight, childhood adiposity, parental obesity, insulin, and leptin
    Arline D Salbe
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Pediatrics 110:299-306. 2002
    ..To assess the effects of body weight, body composition, parental obesity, and metabolic variables on the development of obesity in a large cohort of 5-year-old Native American children with a high propensity for obesity...
  57. ncbi Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus
    Alain D Baron
    Amylin Pharmaceuticals, Inc, 9373 Towne Centre Drive, Suite 250, San Diego, CA 92121, USA
    Curr Drug Targets Immune Endocr Metabol Disord 2:63-82. 2002
    ..Both hormones are deficient in diabetes. Therapies directed at restoring this complex physiology have the potential to facilitate glucose control and thus minimize the attendant complications of diabetes...
  58. ncbi Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps
    Claresa Levetan
    MedStar Clinical Research Center, Washington, DC 20003, USA
    Diabetes Care 26:1-8. 2003
    ....
  59. ncbi Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial
    Priscilla A Hollander
    Baylor University Medical Center, Dallas, Texas, USA
    Diabetes Care 26:784-90. 2003
    ..CONCLUSIONS: Mealtime amylin replacement with pramlintide 120 microg BID, as an adjunct to insulin therapy, improves long-term glycemic and weight control in patients with type 2 diabetes...
  60. ncbi Plasma adiponectin and endogenous glucose production in humans
    Norbert Stefan
    Clinical Diabetes and Nutrition Section, Department of Health and Human Services, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA
    Diabetes Care 26:3315-9. 2003
    ..Whereas associations of plasma adiponectin with muscle insulin sensitivity in humans have been examined, this has not been done for the liver...
  61. ncbi Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion
    Richard E Pratley
    Novartis Pharmaceuticals Corporation, Clinical Research and Development, Diabetes and Obesity Section, One Health Plaza, East Hanover, NJ 07936, USA
    Curr Diab Rep 2:242-8. 2002
    ..Other trials using pharmacologic agents to decrease insulin resistance and increase early insulin secretion are underway. Prevention remains the best hope for a long-term solutions to the worldwide epidemic of diabetes...
  62. ncbi Relation between physical activity and obesity
    Arline D Salbe
    Am J Clin Nutr 78:193-4; author reply 194-5. 2003
  63. ncbi Effect of cortisol on muscle sympathetic nerve activity in Pima Indians and Caucasians
    Barbora Vozarova
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Human Services, Phoenix, Arizona 85016, USA
    J Clin Endocrinol Metab 88:3218-26. 2003
    ..However, an acute release of cortisol is likely to more effectively contain sympathoexcitation during stress in Pima Indians than in Caucasians, which may be an important mechanism of cardioprotection in this Native American population...
  64. ncbi High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes
    Barbora Vozarova
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Diabetes 51:455-61. 2002
    ..These findings are consistent with the hypothesis that a chronic activation of the immune system may play a role in the pathogenesis of type 2 diabetes...